NCT03728673 2026-04-17
A Study Utilizing Escitalopram in Glioma Patients
University of Nebraska
Phase 2 Recruiting
Clinical Trials
27 trialsNCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT05859334 2026-04-13
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05096481 2026-04-08
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05503797 2026-04-03
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
Phase 2 Recruiting
NCT06838676 2026-03-27
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06528691 2026-03-23
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT05188508 2026-03-06
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05607407 2026-03-04
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05683808 2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2 Recruiting
NCT07338539 2026-01-14
BIO-SHORT
Tata Memorial Centre
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT02691923 2025-08-03
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05929495 2025-07-25
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
University of Milano Bicocca
Phase 2 Recruiting
NCT06818331 2025-06-04
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 2 Recruiting
NCT06264388 2025-05-29
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
University of Miami
Phase 2 Recruiting
NCT06016452 2025-04-11
CHROME
Tata Memorial Centre
Phase 2 Recruiting
NCT06687681 2025-04-09
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Kian Immune Cell Company
Phase 2 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT06801730 2025-01-30
NALIRIBVRG
The Central Hospital of Lishui City
Phase 2 Recruiting
NCT06172595 2024-12-03
FET PET in HGG
Singapore General Hospital
Phase 2 Recruiting
NCT06684795 2024-11-12
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT03991832 2024-07-18
SOLID
University Health Network, Toronto
Phase 2 Recruiting